167 related articles for article (PubMed ID: 18989636)
1. Influence of taranabant, a cannabinoid-1 receptor inverse agonist, on pharmacokinetics and pharmacodynamics of warfarin.
Schwartz JI; Dunbar S; Yuan J; Li S; Gipson A; Rosko K; Johnson-Levonas AO; Lasseter KC; Addy C; Stoch AS; Wagner JA
Adv Ther; 2008 Nov; 25(11):1175-90. PubMed ID: 18989636
[TBL] [Abstract][Full Text] [Related]
2. Influence of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, on the pharmacokinetics and pharmacodynamics of warfarin.
Schwartz JI; Liu F; Stroh M; Gipson A; Johnson-Levonas AO; Lasseter KC; Lai E; Wagner JA
Am J Ther; 2009; 16(3):215-23. PubMed ID: 19454860
[TBL] [Abstract][Full Text] [Related]
3. Effect of eslicarbazepine acetate on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects during a three-stage, open-label, multiple-dose, single-period study.
Vaz-da-Silva M; Almeida L; Falcão A; Soares E; Maia J; Nunes T; Soares-da-Silva P
Clin Ther; 2010 Jan; 32(1):179-92. PubMed ID: 20171423
[TBL] [Abstract][Full Text] [Related]
4. Multiple doses of sitagliptin, a selective DPP-4 inhibitor, do not meaningfully alter pharmacokinetics and pharmacodynamics of warfarin.
Wright DH; Herman GA; Maes A; Liu Q; Johnson-Levonas AO; Wagner JA
J Clin Pharmacol; 2009 Oct; 49(10):1157-67. PubMed ID: 19783710
[TBL] [Abstract][Full Text] [Related]
5. Influence of taranabant, an orally active, highly selective, potent cannabinoid-1 receptor (CB1R) inverse agonist, on ethinyl estradiol and norelgestromin plasma pharmacokinetics.
Schwartz JI; Dunbar S; Yuan J; Li S; Miller DL; Rosko K; Johnson-Levonas AO; Lasseter KC; Wagner JA
J Clin Pharmacol; 2009 Jan; 49(1):72-9. PubMed ID: 18936284
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of digoxin in healthy subjects receiving taranabant, a novel cannabinoid-1 receptor inverse agonist.
Denker AE; Morelli G; Vessey LK; Li S; Yuan J; Dunbar S; Lewis NM; Taggart W; Wagner JA
Adv Ther; 2009 Feb; 26(2):230-40. PubMed ID: 19219408
[TBL] [Abstract][Full Text] [Related]
7. Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, for the treatment of obesity: results from a double-blind, placebo-controlled, single oral dose study in healthy volunteers.
Addy C; Li S; Agrawal N; Stone J; Majumdar A; Zhong L; Li H; Yuan J; Maes A; Rothenberg P; Cote J; Rosko K; Cummings C; Warrington S; Boyce M; Gottesdiener K; Stoch A; Wagner J
J Clin Pharmacol; 2008 Apr; 48(4):418-27. PubMed ID: 18258750
[TBL] [Abstract][Full Text] [Related]
8. Multiple-dose pharmacokinetics, pharmacodynamics, and safety of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, in healthy male volunteers.
Addy C; Rothenberg P; Li S; Majumdar A; Agrawal N; Li H; Zhong L; Yuan J; Maes A; Dunbar S; Cote J; Rosko K; Van Dyck K; De Lepeleire I; de Hoon J; Van Hecken A; Depré M; Knops A; Gottesdiener K; Stoch A; Wagner J
J Clin Pharmacol; 2008 Jun; 48(6):734-44. PubMed ID: 18508950
[TBL] [Abstract][Full Text] [Related]
9. The effect of fimasartan, an angiotensin receptor type 1 blocker, on the pharmacokinetics and pharmacodynamics of warfarin in healthy Korean male volunteers: a one-sequence, two-period crossover clinical trial.
Gu N; Kim BH; Lim KS; Kim SE; Nam WS; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
Clin Ther; 2012 Jul; 34(7):1592-600. PubMed ID: 22727611
[TBL] [Abstract][Full Text] [Related]
10. Absence of a pharmacokinetic interaction between etanercept and warfarin.
Zhou H; Patat A; Parks V; Buckwalter M; Metzger D; Korth-Bradley J
J Clin Pharmacol; 2004 May; 44(5):543-50. PubMed ID: 15102876
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics, safety, and tolerability of phentermine in healthy participants receiving taranabant, a novel cannabinoid-1 receptor (CB1R) inverse agonist.
Addy C; Jumes P; Rosko K; Li S; Li H; Maes A; Johnson-Levonas AO; Chodakewitz J; Stoch SA; Wagner JA
J Clin Pharmacol; 2009 Oct; 49(10):1228-38. PubMed ID: 19783715
[TBL] [Abstract][Full Text] [Related]
12. Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.
Jiang X; Williams KM; Liauw WS; Ammit AJ; Roufogalis BD; Duke CC; Day RO; McLachlan AJ
Br J Clin Pharmacol; 2004 May; 57(5):592-9. PubMed ID: 15089812
[TBL] [Abstract][Full Text] [Related]
13. The effect of rofecoxib on the pharmacodynamics and pharmcokinetics of warfarin.
Schwartz JI; Bugianesi KJ; Ebel DL; De Smet M; Haesen R; Larson PJ; Ko A; Verbesselt R; Hunt TL; Lins R; Lens S; Porras AG; Dieck J; Keymeulen B; Gertz BJ
Clin Pharmacol Ther; 2000 Dec; 68(6):626-36. PubMed ID: 11180023
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and pharmacodynamics of warfarin when coadministered with pentosan polysulfate sodium.
Modi NB; Kell S; Simon M; Vargas R
J Clin Pharmacol; 2005 Aug; 45(8):919-26. PubMed ID: 16027402
[TBL] [Abstract][Full Text] [Related]
15. Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics and pharmacodynamics of warfarin.
Kosoglou T; Zhu Y; Xuan F; Black L; Johnson-Levonas AO; Martinho M; Statkevich P; Cutler DL
Eur J Clin Pharmacol; 2012 Nov; 68(11):1509-16. PubMed ID: 22476387
[TBL] [Abstract][Full Text] [Related]
16. Effect of montelukast on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers.
Van Hecken A; Depré M; Verbesselt R; Wynants K; De Lepeleire I; Arnout J; Wong PH; Freeman A; Holland S; Gertz B; De Schepper PJ
J Clin Pharmacol; 1999 May; 39(5):495-500. PubMed ID: 10234597
[TBL] [Abstract][Full Text] [Related]
17. Lack of pharmacokinetic and pharmacodynamic interactions between a smoking cessation therapy, varenicline, and warfarin: an in vivo and in vitro study.
Burstein AH; Clark DJ; O'Gorman M; Willavize SA; Brayman TG; Grover GS; Walsky RL; Obach RS; Faessel HM
J Clin Pharmacol; 2007 Nov; 47(11):1421-9. PubMed ID: 17962429
[TBL] [Abstract][Full Text] [Related]
18. Effect of casopitant, a novel NK-1 receptor antagonist, on the pharmacokinetics and pharmacodynamics of steady-state warfarin.
Kirby LC; Johnson BM; Adams LM; Eberwein DJ; Zhang K; Murray SC; Lates CD; Blum RA; Morris SR
J Clin Pharmacol; 2010 May; 50(5):566-75. PubMed ID: 20220045
[TBL] [Abstract][Full Text] [Related]
19. Lack of effect of lacosamide on the pharmacokinetic and pharmacodynamic profiles of warfarin.
Stockis A; van Lier JJ; Cawello W; Kumke T; Eckhardt K
Epilepsia; 2013 Jul; 54(7):1161-6. PubMed ID: 23614393
[TBL] [Abstract][Full Text] [Related]
20. Lack of drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and warfarin in healthy volunteers.
Macha S; Rose P; Mattheus M; Pinnetti S; Woerle HJ
Diabetes Obes Metab; 2013 Apr; 15(4):316-23. PubMed ID: 23094794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
